Service d'Hépatogastroentérologie, Hôpital Pitié Salpêtrière, Paris, France.
Service de Chirurgie Hépatobiliaire et de Transplantation, Hôpital Pitié Salpêtrière, Paris, France.
Clin Gastroenterol Hepatol. 2015 May;13(5):992-9.e2. doi: 10.1016/j.cgh.2014.10.011. Epub 2014 Oct 20.
BACKGROUND & AIMS: Many patients with alcohol-associated cirrhosis also have diabetes, obesity, or insulin resistance-mediated steatosis, but little is known about how these disorders affect the severity of liver disease. We analyzed the prevalence and prognostic implications of metabolic risk factors (MRFs) such as overweight, diabetes, dyslipidemia, and hypertension in patients with alcohol-associated cirrhosis awaiting liver transplants.
We performed a retrospective study of 110 patients with alcohol-associated cirrhosis (77% male; mean age, 55 y; 71% with >6 mo of abstinence) who received liver transplants at a single center in Paris, France, from 2000 through 2013. We collected data on previous exposure to MRFs, steatosis (>10% in the explant), and histologically confirmed hepatocellular carcinoma (HCC).
HCC was detected in explants from 29 patients (26%). Steatosis was detected in explants from 47 patients (70% were abstinent for ≥6 mo); 50% had a history of overweight or type 2 diabetes. Fifty-two patients (47%) had a history of MRFs and therefore were at risk for nonalcoholic fatty liver disease. A higher proportion of patients with MRF had HCC than those without MRF (46% vs 9%; P < .001). A previous history of overweight or type 2 diabetes significantly increased the risk for HCC (odds ratio, 6.23; 95% confidence interval [CI], 2.47-15.76, and odds ratio, 4.63; 95% CI, 1.87-11.47, respectively; P < .001). MRF, but not steatosis, was associated with the development of HCC (odds ratio, 11.76; 95% CI, 2.60-53; P = .001) independent of age, sex, amount of alcohol intake, or severity of liver disease.
Patients with alcohol-associated cirrhosis who received transplants frequently also had nonalcoholic fatty liver disease. MRFs, particularly overweight, obesity, and type 2 diabetes, significantly increase the risk of HCC.
许多患有酒精性肝硬化的患者还同时患有糖尿病、肥胖症或胰岛素抵抗性脂肪变性,但人们对于这些疾病如何影响肝脏疾病的严重程度知之甚少。我们分析了代谢危险因素(如超重、糖尿病、血脂异常和高血压)在等待肝移植的酒精性肝硬化患者中的流行程度及其预后意义。
我们对 2000 年至 2013 年在法国巴黎的一家中心接受肝移植的 110 例酒精性肝硬化患者(77%为男性;平均年龄 55 岁;71%有≥6 个月的戒酒史)进行了回顾性研究。我们收集了有关以前暴露于代谢危险因素、脂肪变性(>10%在肝移植组织中)和组织学证实的肝细胞癌(HCC)的数据。
在 29 例患者(26%)的肝移植组织中检测到 HCC。在 47 例患者(50%有≥6 个月的戒酒史)的肝移植组织中检测到脂肪变性;50%有超重或 2 型糖尿病病史。52 例(47%)有代谢危险因素史,因此有患非酒精性脂肪性肝病的风险。有代谢危险因素史的患者 HCC 比例高于无代谢危险因素史的患者(46%比 9%;P<.001)。超重或 2 型糖尿病的既往病史显著增加 HCC 的风险(比值比,6.23;95%置信区间[CI],2.47-15.76,和比值比,4.63;95%CI,1.87-11.47,分别;P<.001)。代谢危险因素(但不是脂肪变性)与 HCC 的发展相关(比值比,11.76;95%CI,2.60-53;P=.001),独立于年龄、性别、饮酒量或肝脏疾病严重程度。
接受肝移植的酒精性肝硬化患者常同时患有非酒精性脂肪性肝病。代谢危险因素,尤其是超重、肥胖和 2 型糖尿病,显著增加 HCC 的风险。